Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform enables payload attachment to ‘off-the-shelf’ antibodies in one step without needing to re-engineer or reduce antibodies, resulting in highly homogenous, stable and potent ADC therapies. Learn more
ADCs consist of payloads connected to antibodies through a specific linker. The molecular design enables the highly selective delivery of any payload, often a potent anti-cancer drug, to the diseased tissue, while healthy parts of the human body are spared.
Problems of current ADC technologies:
Poor stability and high heterogeneity: Poor connection of the drug to the antibody can lead to ADC instability, allowing the drug to break apart from the antibody prior to reaching the cancerous cells. It also creates ADCs with a wide range of payloads randomly attached, or a heterogeneous ADC pool, that cannot consistently deliver the same amount of drug. Poor ADC stability ultimately increases risk of unwanted side-effects and reduces efficacy.
Limited linker solubility: Payloads are often hydrophobic and thus tend to induce ADC aggregation, or clumping together, in water-based solutions like blood. When ADCs clump together, they cannot bind to cancerous cells efficiently and have reduced efficacy.
Expensive and time intensive development: Current ADC technologies involve complex engineering efforts and multi-step conjugation procedures that take up significant time and require substantial resources.
We are pioneering a proprietary peptide linker technology that will give us the ability to design and develop homogenous, stable, highly soluble and high-quality ADC products in a cost- and time-effective manner.
Araris’ ADC technology allows for tailor-made manufacturing of safe and highly potent ADC candidates with an improved therapeutic index and the potential to make a clinically meaningful difference for patients with cancer.
As the inventor of the Araris Linker Technology, Philipp has a profound background in Bioconjugation and ADCs. He obtained his Master’s Degree and PhD from ETH Zurich at the interface of Material Science and Protein Engineering. During his post-doctoral work at PSI, he introduced the novel approach using transglutaminases for antibody conjugation that led to the discovery of the Araris Linker Technology.
Isabella holds a Master’s Degree in Molecular Biology from University of Basel and obtained a PhD in Tumorimmunology from University of Zurich (UZH). Before joining Araris, she served as Director Pharmacology at Covagen, a Swiss Biotech that was acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical companies of Johnson & Johnson. She was in charge of the pharmacological characterization of various FynomAbs during pre-clinical development that entered clinical testing.
Dragan received his Master’s degree and PhD in Pharmaceutical Sciences from ETH Zürich. From 2007 to 2014 he was co-founder and CSO of Covagen, a Swiss biotech company acquired in 2014 by an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. He was instrumental in Covagen’s trade sale to Johnson & Johnson, in establishing deals with Roche and Mitsubishi Tanabe and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014. Since 2015 he is a serial entrepreneur and Biotech consultant at Grabulovski Consulting Services.
Martin Behe received his PhD in anorganic chemistry at the University of Basel. He worked at the University Hospitals in Göttingen, Marburg and Freiburg in Germany where he established a group for peptide-based radiopharmaceuticals and its production. Since 2011, Martin Behe leads the Pharmacology group at PSI, where the Araris Linker Technology took its first steps. He has an extensive background in peptide chemistry, peptide labelling and conjugation as well and critically contributed to development of radio-labelled compounds that are used in the clinic.
Rakesh Dixit is an accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, and Medimmune - AstraZeneca. Rakesh was selected by his biopharmaceutical peers as the 100 Most Inspiring People in the Pharmaceutical Industry by PharmaVOICE in 2015. From 2006 to 2019, Rakesh was a Global Vice President of the Biologics R&D at Medimmune - AstraZeneca, where he was a pivotal contributor to the approval of Imfinzi (anti-PD-L1 mAb) for the treatment of lung and bladder cancer; Fasenra (anti-IL-5R afucsolytated mAb) for asthma; Brodalumab (anti-IL-17) in collaboration with Amgen for Psoriasis and Moxetumomab pseudotox (anti-CD22-PEA immunotoxin) for hairy cell leukemia. Rakesh has unique expertise in the development of biologics (e.g., monoclonal antibodies, bispecific biologics, antibody-drug conjugates, fusion proteins, peptides, gene and cell therapies, etc.) and small-molecule biopharmaceuticals. His areas of expertise include discovery, early and late preclinical development, safety assessment, DMPK and translational sciences.
John Lambert joined ImmunoGen Inc. in 1987 and played an important role in translating the technology of ImmunoGen into antibody-drug conjugate (ADC) clinical development programs. These efforts ultimately led to Kadcyla®, one of the first ADCs that was approved by the FDA as well as many additional ADC programs that continue to be developed by ImmunoGen and its partners. He is the author/co-author of more than 120 peer-reviewed scientific publications. In 2016, Dr. Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). Prior to joining ImmunoGen, he served as Assistant Professor of Pathology at the Dana-Farber Cancer Institute of the Harvard Medical School. Dr. Lambert holds a PhD in Biochemistry from University of Cambridge in England and completed his postdoctoral work at the University of California at Davis and Glasgow University in Scotland.
Roger Schibli received his PhD in organic chemistry at the University of Basel, followed by a post-doctoral fellowship at the University of Missouri-Columbia. Since 2010, Roger Schibli holds a full professorship at the Department of Chemistry and Applied Biosciences (ETH Zurich) and heads the Center for Radiopharmaceutical Sciences ETH-PSI-USZ. Roger Schibli pioneered the use of transglutaminases for the site-specific modification of antibodies in his labs at PSI and ETH Zurich more than 10 years ago and is author of many key scientific publications in that area of research. He supports us with his in-dept knowledge about enzymatic modifications of antibodies as well as linker design which is core to the Araris Linker Technology.
Jeff Sharman is a hematologist/oncologist who leads the hematologic malignancy clinical research program for US Oncology. He has been engaged in drug development for lymphoid malignancies including multiple BCR signaling inhibitors, immunotherapies, and antibody drug conjugates He has served as global primary investigator on many trials and has over 60 publications focused on novel therapeutics. He completed his fellowship at Stanford University where he was among the first to propose using BCR signaling antagonists for b cell malignancies and helped lead the initial studies of ibrutinib. He completed his medical residency at Massachusetts General Hospital – part of Harvard University.
Dominik Escher is a founding partner of Pureos Bioventures. He is also a co-founder and Executive Chairman of CDR-Life. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to clinical proof-of-concept, delivering multiple clinically successful products (e.g. Beovu). Dominik obtained his Ph.D. in Molecular Biology from the University of Zurich and also holds a Masters Degree in Education with specialization in Management and Organization from the ETH of Zurich.
As a Managing Partner of VI Partners Arnd Kaltofen is focusing on Healthcare investments. He has collected a long-standing experience in building and exiting ventures. He served on boards of companies such as Esbatech, Kuros Biosurgery, Activaero or Ganymed Pharmaceuticals. In his previous career he built a team dedicated to venture capital transactions in the healthcare industry for KPMG Corporate Finance. He gained his entrepreneurial experience in several medical device and digital health startups. As an MD he started his professional career as an anesthesiologist and in research. Arnd Kaltofen also holds an MBA as well as a Postgraduate Degree in Computer Sciences.
Dmitry ‘Dima’ Kuzmin MSc (Oxon) PhD MRSB MIoD is the co-founder and managing partner of 4BIO Capital, a London-based investment firm focused on advanced therapies and a pioneer of advanced therapies investments. Before founding 4BIO, he served in several academic roles with research interests spanning structural biology and rational design of ion channels, optogenetics, gene therapy of neurological and psychiatric diseases, brain-computer interfaces, and information processing in the brain. He serves or served in the past on several company boards, including Araris Biotech, Redpin Therapeutics, RetroSense Therapeutics (acquired by Allergan), and others.
Michael Sidler has co-founded Redalpine Venture Partners in 2007 and acts as General Partner for the Redalpine funds. Before Redalpine, Michael was responsible for corporate investments and M&A at Prionics AG, a Diagnostics / Biotech company in Schlieren, Switzerland, where under his guidance several acquisitions have been completed. From 1998 to 2003, Michael was with The Boston Consulting Group in Zürich and Toronto as a Consultant and Project Leader in several different industries (e.g. eBanking, Insurance, Automotive etc.) and roles. Michael Sidler holds a PhD in Life Sciences from University of Zürich. He is a member of several organizations, juries and boards for the support of innovation and startups (Venturekick, Swiss Startup Finance) and leads the VC chapter of SECA.
Bernd received his Master’s Degree from University of Surrey, Guildford, UK in applied toxicology and his PhD in Immunology from University of Würzburg (Germany). Prior to joining Araris, Bernd worked as Vice President Oncology Research at Molecular Partners AG. Before that he worked at Janssen/Covagen AG, Merck Serono as well as at Micromet. In these positions he was responsible for the Discovery, Pharmacology, Toxicology and DMPK activities in close collaboration with CMC, Clinical Development as well as Regulatory Affairs ensuring smooth and successful project transitions from research into early and late-stage clinical development. Bernd has in-depth experience in targeted cancer therapy and the development of novel immuno-oncology modalities (e.g. blinatumomab).
In recent times Clive Stanway has chosen to become an independent cancer drug discovery and development advisor. He is a non-executive director for Atelerix Ltd, CytoSeek Ltd and Babraham Bioscience Technologies and serves on the scientific advisory boards of 4Bio Capital and ANGLE plc in addition to his duties for Araris.
Clive was trained as a scientist in cell and molecular biology at Imperial College and Oxford University rising to junior faculty status. He transitioned into cancer drug discovery and development firstly at Xenova and then Prolifix and subsequently at Cancer Research UK where he established and led a team operating to pharmaceutical company standards. Over his career he has been involved in projects which have matured from discovery status into clinical development. For many years, Clive was part of the executive team in the commercial arm of Cancer Research UK and during that time it grew to have an interest in 4 drugs on the market and multimillion pound revenues. He was also an intellectual property contributor to many cancer therapeutic and diagnostic start-up companies and significant driver in the initiation and completion of various deals in the pharmaceutical sector including companies such as Celgene and FORMA Therapeutics.
L. Nathan Tumey is an assistant professor of medicinal chemistry in the School of Pharmacy and Pharmaceutical Sciences at Binghamton University. He joined Binghamton University in 2017, following 15 years of experience in the pharmaceutical and biotechnology industry. Between 2009 - 2017 he was a team leader for the ADC discovery efforts at Pfizer. In this role, he led a group of bioconjugation and bioanalytical scientists that designed and synthesized antibody-drug conjugates for use in oncology applications. He received his PhD in chemistry from Duke University in 2001, under the supervision of Michael Pirrung. His research team at Binghamton University focuses on the application of antibody-drug conjugates and related technology for the treatment of auto-immune disorders and rare diseases. Additionally, his lab investigates bioconjugate stability, ADC linker design and new targeted drug-delivery modalities.
Filippo holds a MSc in Chemistry from University of Turin in Italy, a PhD in Sciences from the School of Pharmacy of the University of Geneva in Switzerland, and a MBA in Business Administration from St. Gallen University - HSG in Switzerland. Filippo initiated his research career in pharmaceutical science at Serono SA. Later, after his MBA, he moved into Business Development where he spent over 10 years before joining Araris. Filippo held various roles in BD&L in small and large organizations such as Roche, Basilea Pharmaceutica and Philogen. In these positions he was responsible for business development activities including in- and out-licensing of both technology platforms and pharmaceutical assets, business case preparation, NPV calculation, term sheet and contract negotiation, and alliance management.
We are backed by a strong investor syndicate: Pureos Bioventures, 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq
We are currently not hiring, please check later.
Our CEO, Philipp Spycher, Ph.D. and CTO, Isabella Attinger-Toller, Ph.D. will be presenting two late-breaking abstracts at this year’s American Association for Cancer Research Meeting in Orlando, Florida. Be sure to stop by our posters on April 18 from 9:00 a.m. – 12:30 p.m. ET
Our Associate Director of ADC Chemistry, Romain Bertrand, Ph.D., will be presenting tomorrow at PEGSEurope in Barcelona. He’ll be presenting preclinical data on our Nectin-4 ADC developed using our proprietary LinkerTechnology. Learn more here: https://www.pegsummiteurope.com/
We’re pleased to announce we’re presenting preclinical data on our anti-CD79b ADC and late-breaking data on an anti-Nectin-4 ADC developed using our proprietary linker technology at this year’s American Association for Cancer Research (AACR) conference.
Visit us at 12th Annual World ADC London 2022: Poster on "Broadening the therapeutic index of antibody-drug conjugates using Araris peptide linkers for site-specific bioconjugation,” will be given on March 30, 2022, at 2:15 p.m. GMT during the conference’s scientific poster session.
We’re excited to announce we’re expanding our Scientific Advisory Board with the appointment of Dr. Jeff Sharman and Dr. Clive Stanway. The two leaders in the field of cancer therapeutics will provide expert support and guidance as we continue preclinical and clinical development of our Antibody Drug Conjugates.
We are very pleased to announce that Araris again ranks among the TOP15 Swiss startups in 2021 after positions 13 in 2020 and 95 in 2019. This is again a great achievement for our company - thanks jury for voting for us! Thank you Araris Team for your hard work!
The winners will be selected on October 12th 2021 during the World ADC Awards Ceremony. Thanks to our supporters for your vote!
Really happy about being listed among so many great companies in Switzerland in Labbiotech.eu.
We are very excited to announce that Araris Biotech AG has appointed Dr. Bernd Schlereth as Chief Development Officer. A warm welcome to the team, Bernd, we are very happy to have you on board!
Very interesting article highlighting the versatility of microbial transglutaminase (MTG) and its use to generate site-specific ADCs
Read about the main issues of the first, second, and third generations of ADCs in the MedNous article below and how we at Araris Biotech AG challenge them.
The new funds will be used to nominate a clinical candidate and advance Araris’ lead programs into preclinical and clinical development, as well as to support the development of a broad proprietary pipeline of ADC compounds.
The investment round is led by: Pureos Bioventures with new investors 4-BIO Capital and btov Partners and existing investors Redalpine, VI Partners and Schroder Adveq.
Araris ranks among the TOP15 Swiss startups in 2020. This is a great achievement for our young company - thanks jury for voting for us! Rank 95 in 2019, Rank 13 in 2020. Thank you Araris Team for your hard work.
Fun insights about our CEO and the Araris Crew...
Pitch session organized by the American Embassy. A great opportunity to present, thanks Venturelab and Ambassador McMullen for the organization.
We are very proud to be chosen among 60 high quality applicants and are looking forward to the experience and learing on the roadshow in Boston.
Zedira published a high level summary on the core of the Araris Linker Technology.
Araris Biotech AG announced today the appointment of Dr. Rakesh Dixit, Dr. John Lambert and Dr. L. Nathan Tumey as members of its Scientific Advisory Board.
Araris announces closing of CHF2.5M seed financing round with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners.
The Venture Kick jury awards MOBBOT and Araris Biotech 130,000 francs each to accelerate the engineering startup and drug-discovery spin-off's speed-to-market. The Swiss startups’ innovations in material science and biotech will benefit the construction and pharmaceutical industries.
Araris Biotech AG announces its incorporation on January 31st 2019.